A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.

Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed. 

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

Researchers have identified new details about the link between certain cancer therapies and heart complications. Could their work lead to key improvements in patient care?

The group will examine data from approximately 1,600 patients, focusing on the relationship between the heart and the aorta. 

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

A new scientific statement from the American Heart Association examined the potential impact of many therapies, including fish oil supplements, lily of the valley and yoga.

The Impella RP System is still associated with significant benefits, the FDA said, but there are certain high-risk patients who should no longer be eligible for treatment.